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Silicosis claim to boost primary health 
care?
Minerals, especially gold, turned South Africa into the economic 
powerhouse of the sub-continent, but only in the past decade has the 
cost in human lives and health begun to be measured and mining 
houses made to pay.
Izindaba’s Chris Bateman looks at what could be a seismic event for 
the gold mining industry: a class action made possible by a landmark 
Constitutional Court ruling last year allowing lung-diseased former 
miners to sue their ex-employers under common law. Until this 
ruling, they had been constrained by two ‘archaic’ inter-acting laws 
that limited claims and acted as a virtual government subsidy to the 
mining industry, adding a huge financial burden to workers’ families 
and the public health system. Now not only do affected miners have a 
better chance of accessing appropriate health care (and the surviving 
families of getting compensation), but the entire primary health care 
system stands to get a much-needed boost as the envisaged Silicosis 
Relief Trust expands an existing network of private GPs, supports 
public health facilities (including mortuaries), and strengthens 
existing tuberculosis field work. Out-of-court settlements for 
asbestosis total R1.1 billion since 2003 – creating trusts and health 
care networks that will need major scaling-up if the current ‘super’ 
claim succeeds.1
Skin closure for caesarean section
A variety of suture materials and skin staples (SS) are used for skin 
closure after caesarean section (CS). Some of these suture materials 
have been associated with lower infection rates, reduced pain, 
improved cosmetic outcomes and cost-effectiveness. Chunder and 
colleagues2 report on their study to determine wound complication 
rates following the use of suture materials and staples for skin closure.
SS are easier to use and are associated with a three- to fourfold 
reduction in time for skin closure. However, they are more expensive 
than suture materials and it is reported that SS are more painful and 
result in a poorer cosmetic appearance.
The overall rate of wound complications following CS in Chunder 
et al.’s study was 7% compared with rates of 0 - 25% in other studies. 
Lower wound complication rates are reported (including by them) 
when the subcutaneous layer was sutured before top skin closure. In 
keeping with the findings of reviews and meta-analyses, they found 
that wound complications were significantly greater when SS were 
used. They therefore recommend that SS not be used for CS skin 
closure in district hospitals.
Helicobacter pylori eradication therapy
Helicobacter pylori is the most common cause of chronic gastritis 
and peptic ulcer disease and a risk factor for gastric adenocarcinoma 
and mucosa-associated lymphoid tissue lymphoma. First-line triple 
therapy for eradication comprises a proton pump inhibitor (PPI) 
and two of the following antibiotics: clarithromycin, metronidazole 
and amoxicillin. However, consensus on the length of treatment 
is lacking. Sokwala and colleagues3 in Kenya compared 7-day and 
14-day regimens to determine the optimal duration of triple therapy 
for H. pylori eradication.
Increasing antimicrobial resistance has resulted in falling 
eradication rates with standard therapies. Clinicians must stress the 
importance of taking the medications as prescribed to minimise 
the likelihood of antibiotic resistance developing, as this is a major 
cause of treatment failure. The prevalence of H. pylori antimicrobial 
resistance shows regional variation within and between countries, 
and the use of alternative antibiotics based on local resistance rates 
may improve eradication rates. 
Compliance with antimicrobial therapy is improved with short-
duration therapy. This is particularly relevant with H. pylori 
eradication regimens because side-effects such as diarrhoea or taste 
disturbance can lead to discontinuation of therapy in some patients. 
The authors’ finding that 1-week and 2-week triple treatments are 
similar in terms of efficacy, safety and patient compliance therefore 
has valuable clinical implications.
Aminoglycoside-induced hearing loss
Multidrug-resistant tuberculosis (MDR TB, i.e. Mycobacterium 
tuberculosis resistant to both isoniazid and rifampicin with 
or without other drug resistance) is an increasing problem, 
especially in sub-Saharan Africa, where the significant increase in 
MDR-TB has been linked to the human immunodeficiency virus 
(HIV) epidemic. The second-line injectable drugs (amikacin, 
kanamycin, capreomycin) have significant adverse effects, 
especially ototoxicity and nephrotoxicity. Unlike nephrotoxicity, 
ototoxicity is permanent. 
Harris and colleagues4 investigated the incidence of ototoxicity in 
HIV-positive and HIV-negative patients with MDR-TB and provide 
clinical guidelines relating to ototoxicity. They studied MDR-TB 
patients with normal hearing and middle ear status at baseline, 
at Brooklyn Chest Hospital in Cape Town. Fifty-seven per cent 
developed high-frequency hearing loss. HIV-positive patients (70%) 
were more likely to develop hearing loss than HIV-negative patients 
(42%). 
Owing to the long half-life of aminoglycosides in cochlear tissue, 
patients should be monitored for up to about 6 months after 
completion of MDR therapy. The authors conclude that auditory 
monitoring and auditory rehabilitation should be an integral part of 
the package of care of MDR-TB patients.
UCT 100th anniversary issue
The part two of this issue of SAMJ comprises contributions from 
the University of Cape Town Faculty of Health Sciences. Material 
ranges from historical and reflective to many research papers. The 
scale of the exercise required the appointment of a section editor, 
Professor Jane Seggie, who spent a sabbatical at the journal managing 
the exercise. We wish the faculty everything of the best for the next 
100 years!
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